Hospital for Children and Adolescents, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Ann Med. 2012 Sep;44(6):578-87. doi: 10.3109/07853890.2011.590521. Epub 2011 Oct 13.
Glucocorticoid therapy is used in the treatment of moderate to severe inflammatory bowel disease (IBD). However, IBD patients display varying degrees of glucocorticoid sensitivity: some respond rapidly to the given treatment, whereas others show no response, or develop steroid therapy-related side-effects. At present, we cannot foresee whether the patient will benefit from the administered glucocorticoids or not. During the past 10 years, numerous attempts have been made to provide the means to identify and predict steroid therapy-sensitive patients in advance. This would be vital to avoid unnecessary glucocorticoid exposure in patients that do not respond to treatment with steroids. Here we provide a concise review of recent developments regarding the molecular basis of glucocorticoid sensitivity in IBD patients and the methods employed to assess it.
糖皮质激素治疗被用于治疗中重度炎症性肠病（IBD）。然而，IBD 患者对糖皮质激素的敏感性存在差异：有些患者对治疗有快速反应，而有些患者则没有反应，或出现皮质类固醇治疗相关的副作用。目前，我们无法预见患者是否会从给予的糖皮质激素中受益。在过去的 10 年中，人们已经做出了许多尝试，以提供提前识别和预测糖皮质激素治疗敏感患者的方法。这对于避免对皮质类固醇治疗无反应的患者不必要地暴露于糖皮质激素至关重要。在这里，我们对 IBD 患者糖皮质激素敏感性的分子基础以及评估其方法的最新进展进行了简要综述。
